Art

J-GLOBAL ID：202102272371825386   Reference number：21A0100003

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives

PD-1/PD-L1遮断癌免疫療法に対する耐性:メカニズム,予測因子,および将来の展望【JST・京大機械翻訳】

Author (12)： Sun Jin-Yu (The First College of Clinical Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing, China) ,  Zhang Dengke (Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Lishui Hospital of Zhejiang University/ The Fifth Affiliated Hospital of Wenzhou Medical University/ Clinical Medicine of Center Hospital of Lishui College, Lishui, China) ,  Zhang Dengke (College of Medicine, Lishui College, Lishui, China) ,  Wu Songquan (Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Lishui Hospital of Zhejiang University/ The Fifth Affiliated Hospital of Wenzhou Medical University/ Clinical Medicine of Center Hospital of Lishui College, Lishui, China) ,  Wu Songquan (College of Medicine, Lishui College, Lishui, China) ,  Xu Min (Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Lishui Hospital of Zhejiang University/ The Fifth Affiliated Hospital of Wenzhou Medical University/ Clinical Medicine of Center Hospital of Lishui College, Lishui, China) ,  Xu Min (College of Medicine, Lishui College, Lishui, China) ,  Zhou Xiao (Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China) ,  Lu Xiao-Jie (Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China) ,  Ji Jiansong (Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Lishui Hospital of Zhejiang University/ The Fifth Affiliated Hospital of Wenzhou Medical University/ Clinical Medicine of Center Hospital of Lishui College, Lishui, China) ,  Ji Jiansong (College of Medicine, Lishui College, Lishui, China) ,  Ji Jiansong (Department of radiology, Affiliated Lishui Hospital of Zhejiang University, Lishui, China)
Material： Biomarker Research (Web)
Volume： 8  Issue： 1  Page： 1-10  Publication year： 2020 
JST Material Number： U7304A  ISSN： 2050-7771  Document type： Article
Article type： 文献レビュー  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Abstract/Point： PD-1/PD-L1 blockade therapy is...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=21A0100003&from=J-GLOBAL&jstjournalNo=U7304A") }}

Thesaurus term： *immunotherapy ,  effectiveness
Semi thesaurus term： 悪性腫瘍 ,  腫瘍進行 ,  臨床医 ,  *癌免疫療法 ,  癌治療 ,  治療抵抗性 ,  *予測因子 , 【Automatic Indexing@JST】

Author keywords (3)： PD-1/PD-L1 blockade ,  Cancer immunotherapy ,  Resistance

JST classification (1)： Immunotherapy for tumors  (GE03035B)

Reference (98)：

• N Engl J Med; Nivolumab plus Ipilimumab in advanced non-small-cell lung Cancer; MD Hellmann, L Paz-Ares, R Bernabe Caro, B Zurawski, SW Kim, E Carcereny Costa; 381; 21; 2019; 2020-2031; citation_id=CR1
• Eur Urol; Programmed Death-1 or programmed death Ligand-1 blockade in patients with platinum-resistant metastatic Urothelial Cancer: a systematic review and meta-analysis; SA Niglio, R Jia, J Ji, S Ruder, VG Patel, A Martini; 76; 6; 2019; 782-789; citation_id=CR2
• Cancer Lett; Cancer immunotherapy: current applications and challenges; JY Sun, XJ Lu; 480; 2020; 1-3; citation_id=CR3
• Nat Immunol; Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups; LP Andrews, H Yano, DAA Vignali; 20; 11; 2019; 1425-1434; citation_id=CR4
• Prestipino A, Zeiser R. Clinical implications of tumor-intrinsic mechanisms regulating PD-L1. Sci Transl Med. 2019;11(478).

Terms in the title (8)： PD-1 ,  PD-L1 ,  遮断 ,  癌免疫療法 ,  耐性 ,  メカニズム ,  予測因子 ,  展望